GNFT Genfit S.A. Stock Quote

GNFT [NASD]

Index	-	P/E	4.24	EPS (ttm)	1.10	Insider Own	-	Shs Outstand	51.45M	Perf Week	0.86%
Market Cap	240.79M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	43.23M	Perf Month	23.16%
Income	69.40M	PEG	-	EPS next Q	-	Inst Own	4.20%	Short Float	0.69%	Perf Quarter	42.25%
Sales	88.30M	P/S	2.73	EPS this Y	146.40%	Inst Trans	-0.60%	Short Ratio	9.80	Perf Half Y	14.71%
Book/sh	0.71	P/B	6.56	EPS next Y	-	ROA	-	Target Price	8.48	Perf Year	23.16%
Cash/sh	4.45	P/C	1.05	EPS next 5Y	-	ROE	-	52W Range	3.01 - 6.38	Perf YTD	-6.40%
Dividend	-	P/FCF	-	EPS past 5Y	29.40%	ROI	34.30%	52W High	-28.21%	Beta	1.50
Dividend %	-	Quick Ratio	-	Sales past 5Y	66.10%	Gross Margin	98.30%	52W Low	52.16%	ATR	0.33
Employees	112	Current Ratio	-	Sales Q/Q	2810.40%	Oper. Margin	-	RSI (14)	59.98	Volatility	7.12% 7.22%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	2.16	Prev Close	4.68
Shortable	Yes	LT Debt/Eq	-	Earnings	May 11 AMC	Payout	-	Avg Volume	30.24K	Price	4.58
Recom	-	SMA20	4.10%	SMA50	18.64%	SMA200	18.26%	Volume	30,741	Change	-2.14%

Dec-20-21

Upgrade

H.C. Wainwright

Neutral → Buy

Jul-23-20

Upgrade

Stifel

Hold → Buy

Jun-25-20

Initiated

BofA/Merrill

Underperform

May-13-20

Downgrade

Kepler

Buy → Reduce

May-12-20

Downgrade

H.C. Wainwright

Buy → Neutral

$46 → $11

May-12-20

Downgrade

Barclays

Overweight → Equal Weight

$55 → $14

Oct-29-19

Reiterated

B. Riley FBR

Buy

$52 → $43

Jun-25-19

Initiated

Stifel

Hold

Apr-24-19

Initiated

SVB Leerink

Outperform

$58

Apr-22-19

Initiated

Barclays

Overweight

Jul-08-22 04:10PM	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial GlobeNewswire
11:12AM	The NASH Drug Dream Isnt Dead Yet. Intercept is Asking FDA for Approval Again. Barrons.com
May-25-22 04:10PM	GENFIT: May 25, 2022 Combined Shareholders Meeting results GlobeNewswire
May-11-22 04:10PM	GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS) GlobeNewswire +7.58%
Apr-29-22 04:10PM	GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022 GlobeNewswire
Apr-20-22 04:10PM	GENFIT Annual Combined General Meeting of May 25, 2022 Availability of Preparatory Documents GlobeNewswire
Apr-14-22 12:00PM	What Makes GENFIT S.A. Unsponsored ADR (GNFT) a New Buy Stock Zacks
Apr-07-22 04:10PM	GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update GlobeNewswire
Feb-28-22 04:10PM	GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021 GlobeNewswire
Jan-24-22 04:10PM	GENFIT: 2022 Financial Calendar GlobeNewswire -7.83%
Jan-21-22 04:10PM	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial GlobeNewswire
Jan-11-22 10:00AM	Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect? Zacks
Dec-23-21 10:00AM	How Much Upside is Left in GENFIT S.A. Unsponsored ADR (GNFT)? Wall Street Analysts Think 60% Zacks
Dec-17-21 11:42AM	GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Genfit as Shares Go Gangbusters InvestorPlace +53.31%
06:25AM	Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful Benzinga
01:15AM	On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset GlobeNewswire
01:00AM	Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership Business Wire
01:00AM	GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership GlobeNewswire
Nov-18-21 04:15PM	GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technologys Unique Performance in Identifying Patients with at-risk NASH GlobeNewswire
Nov-09-21 04:10PM	GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program GlobeNewswire
Nov-08-21 04:10PM	GENFIT: Third Quarter 2021 Financial Information GlobeNewswire
Nov-02-21 05:10PM	New Clinical Data on GENFITs Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting® GlobeNewswire
Sep-29-21 04:10PM	GENFIT Reports First Half-Year 2021 Financial Results and Provides Corporate Update GlobeNewswire
Jul-09-21 04:10PM	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial GlobeNewswire
Jun-30-21 04:10PM	GENFIT: June 30, 2021 Annual Shareholders Meeting results GlobeNewswire
Jun-24-21 04:10PM	GENFIT obtains non-dilutive financing of 11 million in the form of a State Guaranteed Loan GlobeNewswire
Jun-23-21 04:10PM	GENFIT presents new NIS4® data in NASH at the International Liver Congress and the 81st Scientific Sessions of the American Diabetes Association GlobeNewswire
Jun-18-21 12:52PM	Hedge Funds Are Betting On Genfit SA (GNFT) Insider Monkey
Jun-15-21 04:10PM	GENFIT: June 15, 2021 Combined Shareholders Meeting: Wide support for the resolutions submitted to the shareholders vote but quorum not met on first convening GlobeNewswire
May-27-21 04:10PM	GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021 GlobeNewswire
May-12-21 04:10PM	GENFIT: Reports First Quarter 2021 Financial Information GlobeNewswire
May-11-21 04:10PM	GENFIT Provides Pipeline Update and Launch of New Clinical Programs GlobeNewswire
May-10-21 04:10PM	GENFIT Annual Combined General Meeting of June 15, 2021 - Availability of Preparatory Documents GlobeNewswire
May-03-21 02:10AM	GENFIT announces the launch by Labcorp of NASHnext® A Novel Noninvasive Diagnostic Test Powered by GENFITs NIS4 Technology to Identify Patients with At-Risk NASH GlobeNewswire +5.12%
Apr-23-21 12:30PM	GENFIT: Publication of the 2020 Universal Registration Document and the 2020 Annual Report on Form 20-F; Annual Shareholders Meeting to take place on June 15, 2021 GlobeNewswire
Apr-22-21 04:10PM	GENFIT hires Thomas Baetz as Chief Financial Officer and adds two new members to its Executive Committee GlobeNewswire
Apr-01-21 04:10PM	GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update GlobeNewswire
Mar-04-21 04:10PM	GENFIT appoints Jean-François Tiné to the Board of Directors GlobeNewswire
Mar-01-21 04:05PM	Indus Announces Launch of Public Offering of 1,750,000 Shares of Common Stock GlobeNewswire
Feb-26-21 04:10PM	GENFIT: Revenues and Cash Position as of December 31, 2020 GlobeNewswire
Feb-23-21 10:50AM	Rhizome Partners: INDUS (INDT) Looks, Feels, and Talks Like a Billion-Dollar Public REIT Insider Monkey
Feb-22-21 04:10PM	GENFIT: new market research data highlight potential of elafibranor in PBC GlobeNewswire -5.02%
Feb-18-21 05:00PM	INDUS Announces Fiscal 2020 Fourth Quarter and Fiscal 2020 Results GlobeNewswire
Feb-12-21 05:00PM	INDUS Announces Fiscal 2020 Fourth Quarter and Full Year Earnings Webcast GlobeNewswire
Feb-10-21 04:10PM	GENFIT: 2021 Financial Calendar GlobeNewswire +14.56%
12:16PM	Why Genfit Stock Is Skyrocketing Today Motley Fool
07:34AM	The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga
06:42AM	Genfit Pops 29% Pre-Market On Positive Data From Liver Disease Therapy Study SmarterAnalyst
Feb-09-21 04:10PM	GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology GlobeNewswire
Jan-28-21 04:10PM	GENFIT Announces Two Key Appointments to the Executive Committee GlobeNewswire
Jan-27-21 03:30PM	GENFIT: Technical Corrections to the Results of the January 25, 2021 Bondholders Meeting with No Impact on Resolutions Approval GlobeNewswire
Jan-25-21 01:30PM	GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms GlobeNewswire
Jan-13-21 04:15PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Genfit SA and Encourages Investors with Losses of $100,000 to Contact the Firm Business Wire
04:10PM	GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021 and informs the OCEANEs holders of certain procedures for the Bondholders Meeting of January 25, 2021 GlobeNewswire
Jan-12-21 02:15PM	January 13, 2021 Extraordinary Shareholders Meeting: Wide support for the resolutions submitted to the shareholders vote but quorum not met on first convening GlobeNewswire
Jan-11-21 04:10PM	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial GlobeNewswire
Jan-08-21 12:30PM	GENFIT Informs its Shareholders of Certain Procedures for the Extraordinary General Meeting of January 13, 2021 GlobeNewswire
Jan-06-21 04:10PM	GENFIT to Present at Upcoming Investor Conferences and Host a PBC KOL Event GlobeNewswire
Dec-23-20 03:11PM	Shareholder Alert: Robbins LLP Announces That Genfit SA (GNFT) is Being Sued for Misleading Shareholders Business Wire
02:00PM	The Law Offices of Frank R. Cruz Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors Business Wire
12:00PM	INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors Business Wire
Dec-22-20 07:38PM	Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Genfit S.A. (GNFT) on Behalf of Investors Business Wire
04:10PM	GENFIT: Renegotiation of the OCEANEs Convertible Bond Terms: Availability of Prospectus Relating to the Admission of New Shares Following Conversion of the OCEANEs GlobeNewswire
Dec-07-20 02:10AM	GENFIT announces the successful completion of a key milestone in the partial buyback and amendment of its OCEANEs GlobeNewswire
Nov-30-20 02:10AM	GENFIT announces satisfactory preliminary results of its OCEANEs partial buyback offer GlobeNewswire
Nov-23-20 02:15AM	GENFIT Announces Final Terms For Proposed Renegotiation of 2022 OCEANE Convertible Bonds GlobeNewswire
Nov-16-20 04:10PM	GENFIT: New Data Presented at AASLD The Liver Meeting Digital Experience GlobeNewswire
02:30AM	GENFIT: Third Quarter 2020 Financial Information and Launch of Renegotiation of Convertible Bond GlobeNewswire
Sep-30-20 04:05PM	GENFIT: First Half-Year 2020 Financial Report and New Corporate Strategy GlobeNewswire
02:30PM	Genfit SA to Host Earnings Call ACCESSWIRE
Sep-28-20 02:00AM	GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease GlobeNewswire +31.26%
Sep-25-20 07:37AM	The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs Benzinga +14.17%
Sep-24-20 04:10PM	GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC GlobeNewswire -5.05%
Sep-22-20 04:10PM	GENFIT To Announce First Half-Year 2020 Financial Results and New Corporate Strategy on September 30, 2020 GlobeNewswire -7.06%
Sep-02-20 11:20AM	Intercept Pharmaceuticals Will Lay Off a Quarter of Its Staff as NASH Dream Fades Barrons.com
Aug-26-20 04:10PM	GENFIT Announces Two Oral Presentations at the Digital International Liver Congress 2020 GlobeNewswire
Aug-05-20 07:35AM	The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings Benzinga
02:30AM	GENFIT Announces Pivotal Publication of NIS4 Technology to Identify Patients with At-Risk NASH in The Lancet Gastroenterology & Hepatology GlobeNewswire
Jul-23-20 11:02AM	A Top Contender in the Race for a NASH Drug Drops Out Barrons.com
Jul-22-20 04:05PM	GENFIT: Provides Initial Update on Corporate Strategy GlobeNewswire
Jul-10-20 04:05PM	GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial GlobeNewswire
Jun-30-20 10:29AM	Intercept Slumps as the FDA Issues CRL to NASH Candidate Zacks
Jun-29-20 04:05PM	Intercept Shares Tumble on NASH Disappointment Barrons.com
Jun-15-20 05:19PM	Many 'Ifs' Surrounding Viking Therapeutics GuruFocus.com
Jun-10-20 08:36AM	Is Genfit (GNFT) Stock a Solid Choice Right Now Zacks
May-26-20 01:19PM	Intercept Down on Postponement of AdCom Meet for NASH Drug Zacks
May-14-20 05:31PM	After Drug Failure, Genfit's Cupboard Is Nearly Bare GuruFocus.com -6.31%
May-12-20 02:20PM	Here's Why Shares of Durect Jumped Higher Today Motley Fool -67.73%
01:17PM	Why Genfit Is Cratering Today Motley Fool
11:03AM	GNFT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Genfit SA and Encourages Investors to Contact the Firm ACCESSWIRE
08:06AM	The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings Benzinga
04:39AM	Genfit Craters 49% On Failed NASH Trial; Top Analyst Not Surprised SmarterAnalyst
04:35AM	Genfit Plunges After Liver Medicine Falls Short in Study Bloomberg
May-11-20 05:52PM	This Biotech Just Lost Half Its Value After A Key Hepatitis Drug Failed Investor's Business Daily
Apr-17-20 08:43AM	Why Genfit (GNFT) Stock Might be a Great Pick Zacks
Apr-11-20 02:32AM	Genfit SA (EPA:GNFT) Just Released Its Full-Year Earnings: Here's What Analysts Think Simply Wall St.
Mar-30-20 06:06PM	FDA Decisions on 5 Drugs Expected in 2nd Quarter GuruFocus.com
Mar-04-20 04:26PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Genfit SA - GNFT GlobeNewswire
Mar-03-20 02:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Genfit SA - GNFT ACCESSWIRE
Mar-02-20 05:35PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Genfit SA - GNFT PR Newswire

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience